125 related articles for article (PubMed ID: 27550449)
1. Interleukin-30 Promotes Breast Cancer Growth and Progression.
Airoldi I; Cocco C; Sorrentino C; Angelucci D; Di Meo S; Manzoli L; Esposito S; Ribatti D; Bertolotto M; Iezzi L; Natoli C; Di Carlo E
Cancer Res; 2016 Nov; 76(21):6218-6229. PubMed ID: 27550449
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome.
Sorrentino C; Ciummo SL; D'Antonio L; Fieni C; Lanuti P; Turdo A; Todaro M; Di Carlo E
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663639
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization.
Sorrentino C; Ciummo SL; Cipollone G; Caputo S; Bellone M; Di Carlo E
Cancer Res; 2018 May; 78(10):2654-2668. PubMed ID: 29487200
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.
Sorrentino C; D'Antonio L; Ciummo SL; Fieni C; Landuzzi L; Ruzzi F; Vespa S; Lanuti P; Lotti LV; Lollini PL; Di Carlo E
J Hematol Oncol; 2022 Oct; 15(1):145. PubMed ID: 36224639
[TBL] [Abstract][Full Text] [Related]
5. Hindering triple negative breast cancer progression by targeting endogenous interleukin-30 requires IFNγ signaling.
Sorrentino C; Ciummo SL; D'Antonio L; Lanuti P; Abrams SI; Yin Z; Lu LF; Di Carlo E
Clin Transl Med; 2021 Feb; 11(2):e278. PubMed ID: 33635005
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways.
Ciummo SL; Sorrentino C; Fieni C; Di Carlo E
J Exp Clin Cancer Res; 2023 Dec; 42(1):336. PubMed ID: 38087324
[TBL] [Abstract][Full Text] [Related]
7. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival.
D'Antonio L; Fieni C; Ciummo SL; Vespa S; Lotti L; Sorrentino C; Di Carlo E
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36927528
[TBL] [Abstract][Full Text] [Related]
9. Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
Sirkisoon SR; Carpenter RL; Rimkus T; Anderson A; Harrison A; Lange AM; Jin G; Watabe K; Lo HW
Oncogene; 2018 May; 37(19):2502-2514. PubMed ID: 29449694
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity in breast carcinoma cells with increased invasive capacities.
Negro G; Aschenbrenner B; Brezar SK; Cemazar M; Coer A; Gasljevic G; Savic D; Sorokin M; Buzdin A; Callari M; Kvitsaridze I; Jewett A; Vasileva-Slaveva M; Ganswindt U; Skvortsova I; Skvortsov S
Radiol Oncol; 2020 Feb; 54(1):103-118. PubMed ID: 32061169
[TBL] [Abstract][Full Text] [Related]
11. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
12. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit tumor growth of human triple negative breast cancer.
Zhu Z; Wang S; Zhu J; Yang Q; Dong H; Huang J
Biol Chem; 2016 Oct; 397(10):1087-95. PubMed ID: 27186677
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
[TBL] [Abstract][Full Text] [Related]
15. High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma.
Li X; Wei B; Sonmez C; Li Z; Peng L
Hum Pathol; 2017 Aug; 66():222-229. PubMed ID: 28655638
[TBL] [Abstract][Full Text] [Related]
16. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
17. The circular RNA circEIF3M promotes breast cancer progression by promoting cyclin D1 expression.
Li X; Ren Z; Yao Y; Bao J; Yu Q
Aging (Albany NY); 2020 Jul; 12(14):14775-14790. PubMed ID: 32652519
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-22 promotes development of malignant lesions in a mouse model of spontaneous breast cancer.
Katara GK; Kulshrestha A; Schneiderman S; Riehl V; Ibrahim S; Beaman KD
Mol Oncol; 2020 Jan; 14(1):211-224. PubMed ID: 31725949
[TBL] [Abstract][Full Text] [Related]
19. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
